Wolfson Centre for Stem Cells, Tissue Engineering & Modelling, University of Nottingham, University Park, Nottingham, UK.
J Cardiovasc Transl Res. 2012 Oct;5(5):581-92. doi: 10.1007/s12265-012-9376-5. Epub 2012 May 26.
Functional cardiomyocytes can be efficiently derived from human pluripotent stem cells (hPSCs), which collectively include embryonic and induced pluripotent stem cells. This cellular platform presents exciting new opportunities for development of pharmacologically relevant in vitro screens to detect cardiotoxicity, validate novel drug candidates in preclinical trials and understand complex congenital cardiovascular disorders, to advance current clinical therapies. Here, we discuss the progress and impediments the field has faced in using hPSC-derived cardiomyocytes for these in vitro applications, and highlight that rigorous protocol optimisation and standardisation, scalability and automation are remaining obstacles for the generation of pure, mature and clinically relevant hPSC cardiomyocytes.
功能性心肌细胞可以从人多能干细胞（hPSC）中高效获得，这些细胞包括胚胎干细胞和诱导多能干细胞。该细胞平台为开发药物相关的体外筛选方法提供了新的机会，可以检测心脏毒性，在临床前试验中验证新药候选物，并了解复杂的先天性心血管疾病，从而推进当前的临床治疗方法。在这里，我们讨论了该领域在使用 hPSC 衍生的心肌细胞进行这些体外应用时所面临的进展和障碍，并强调严格的方案优化和标准化、可扩展性和自动化仍然是生成纯净、成熟和具有临床相关性的 hPSC 心肌细胞的障碍。
